Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial

Blood. 2017 Apr 20;129(16):2328-2330. doi: 10.1182/blood-2017-01-764258. Epub 2017 Mar 6.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Brentuximab Vedotin
  • Disease-Free Survival
  • Female
  • Humans
  • Immunoconjugates / administration & dosage*
  • Immunoconjugates / adverse effects
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Lymphoma, Large B-Cell, Diffuse / mortality*
  • Male
  • Mediastinal Neoplasms / drug therapy*
  • Mediastinal Neoplasms / mortality*
  • Middle Aged
  • Recurrence
  • Survival Rate

Substances

  • Immunoconjugates
  • Brentuximab Vedotin